PMGC unit advances EL-32 U.S. manufacturing
NorthStrive Biosciences (NASDAQ: ELAB) announced on April 13, 2026 the U.S. transfer of its EL-32 Working Cell Bank (WCB) to a third-party fermentation facility and the start of a manufacturing optimization program to raise yield and enable scalable, cost-efficient production.
EL-32 is a dual-action engineered probiotic targeting myostatin and activin-A pathways to help preserve lean muscle during GLP-1 therapy. Collaboration with Modulant Biosciences covers process development for animal-health products while NorthStrive retains human therapeutic rights, aiming to support IND-enabling activities and future GMP manufacturing.
Loading…
Loading translation…
Positive
- EL-32 WCB transferred to a U.S. fermentation facility
- Manufacturing optimization program initiated to improve production yield
- Dual-track strategy preserves human rights while enabling animal-health commercialization
Negative
- No IND or GMP timeline disclosed in the announcement
- Reliance on a third-party facility for upstream/downstream process development
Equity facility size
$20,000,000
Equity purchase facility with Streeterville Capital
Registered common stock
$4,551,804
Common stock registered in 424B5 related to ELOC
Net loss
$7,747,813
Year ended Dec 31, 2025 (10-K)
Accumulated deficit
$21,017,440
As of Dec 31, 2025 (10-K)
Net working capital
$2,928,959
As of Dec 31, 2025 (10-K)
Shares outstanding
1,159,112
Common shares outstanding as of Mar 30, 2026
Partnership commitments
$4,900,000
Top-line revenue commitments over five years from prior distribution deals
Average partnership move
7.62%
Average 24h move on prior partnership-tagged news
$4.79
Last Close
Volume
Volume 5,141,325 is about 76% below recent average 21,086,615, suggesting muted pre-news trading.
low
Technical
Price 4.79 is well below the 200-day MA at 97.04, reflecting a prolonged downtrend.
ELAB showed a -8.94% move while close peers were mixed: INDP +14.05%, QLGN +7.72%, UBX -29.14%, REVB -4.88%, SPRC +1.13%. Momentum scanner also flagged DRMA up and INDP down, reinforcing stock-specific dynamics rather than a unified biotech sector move.
Date
Event
Sentiment
Move
Catalyst
Apr 29
Positive
+7.6%
Distribution agreements securing up to $4.9M in multi-year revenue commitments.
Pattern Detected
Prior partnership news for ELAB was followed by a positive move, whereas this partnership-related milestone appears against a sharply depressed share price near 52-week lows.
Recent Company History
Recent history shows PMGC/ELAB pursuing a multi-sector strategy, including biotech, precision manufacturing, and packaging. A key prior partnership event on Apr 29, 2024 highlighted global distribution agreements securing up to $4.9M in potential revenue commitments and coincided with a +7.62% move. The current EL-32 collaboration and manufacturing optimization extends the partnership theme into dual human and animal health applications, building on the company’s earlier focus on commercial alliances to unlock platform value.
+7.6%
Average Historical Move
partnership
Past partnership news for ELAB led to an average +7.62% move. The new EL-32 collaboration similarly targets multi-year value creation but in biotech and animal health rather than aesthetics.
Partnership strategy has progressed from revenue-sharing distribution deals in aesthetics to platform collaborations spanning human therapeutics and non-human animal health applications.
This announcement advances EL-32 toward clinical readiness by moving its Working Cell Bank to a U.S. precision fermentation facility and launching manufacturing optimization for dual human and animal health uses. It also extends ELAB’s history of partnership-driven growth, echoing earlier deals tied to up to $4.9M in commitments. Against a backdrop of net losses and going concern risk, investors may watch for concrete IND-enabling milestones and funding developments tied to this program.
myostatin
medical
“EL-32 is a dual-action engineered probiotic therapeutic designed to express both myostatin and activin-A antigens”
Myostatin is a naturally occurring protein produced by muscle that acts like a brake, limiting how big and strong muscles can grow. Because medicines that block myostatin can allow muscles to increase in size and strength, investors follow related drug programs closely for their potential to treat muscle-wasting diseases and age-related weakness; trial results, safety and regulatory approval prospects can materially affect a company’s value.
activin-a
medical
“dual-action engineered probiotic therapeutic designed to express both myostatin and activin-A antigens”
Activin-A is a naturally occurring protein that helps control cell growth, inflammation and tissue repair, acting like a traffic signal that tells cells when to divide, specialize or calm down. It matters to investors because abnormal levels or activity can be a marker for diseases or a target for drugs and tests, so findings about activin-A can influence the prospects of therapies, diagnostics, clinical trial outcomes and regulatory decisions.
antigens
medical
“engineered probiotic therapeutic designed to express both myostatin and activin-A antigens”
Antigens are molecules—often proteins—on the surface of viruses, bacteria, or abnormal cells that the immune system recognizes as foreign, like a mugshot or ID badge that flags an intruder. For investors, antigens matter because they are the targets for vaccines, diagnostic tests and many biologic drugs; which antigen is involved affects how well a product works, how regulators evaluate it and how large the market opportunity may be.
glp-1 receptor agonist
medical
“addressing metabolic dysfunction in patients undergoing GLP-1 receptor agonist weight loss therapy”
A GLP-1 receptor agonist is a medicine that mimics a natural gut hormone to trigger insulin release, slow stomach emptying, and curb appetite — like using a key to turn on a lock that controls blood sugar and hunger signals. For investors, these drugs matter because they treat common conditions such as diabetes and obesity, can drive large prescription and sales growth, reshape healthcare costs, and heavily affect drug pipelines, competition and company valuations.
working cell bank
technical
“successful transfer of the EL-32 Working Cell Bank (“WCB”) to a U.S.-based third-party fermentation facility”
A working cell bank is a prepared, stored supply of living cells used repeatedly to make a biologic product during routine manufacturing, acting like a reliable “starter” batch for production. It matters to investors because the quality and stability of that starter determine consistency, regulatory approval, production speed and cost—similar to using the same proven recipe and starter yeast to ensure each batch of bread turns out the same and is safe to sell.
precision fermentation
technical
“retained the third-party precision fermentation facility to lead upstream and downstream process development”
Precision fermentation uses edited microbes (like yeast or bacteria) as tiny, programmable factories to produce a single, specific ingredient—such as a protein, enzyme or flavor—rather than making whole foods. Think of it like coding a vending machine to dispense one exact product on demand. For investors, it matters because it can cut production costs, speed up scale-up, reduce reliance on traditional agriculture or chemical synthesis, and create new, high-margin products that can reshape markets and regulatory pathways.
investigational new drug
regulatory
“support investigational new drug (“IND”)-enabling activities and future good manufacturing practices”
An investigational new drug is a medication that is still being tested in clinical trials to determine if it is safe and effective for treating a specific condition. For investors, it represents a potential breakthrough that could lead to a new treatment and significant financial gains if successful, but also carries risks since it has not yet been approved for widespread use.
good manufacturing practices
regulatory
“support investigational new drug (“IND”)-enabling activities and future good manufacturing practices (“GMP”) manufacturing”
Good manufacturing practices are a set of required processes, controls and documentation that ensure products are made consistently, safely and to quality standards — like following a precise recipe in a clean kitchen so every batch turns out the same. For investors, compliance matters because it affects a maker’s ability to get regulatory approval, avoid costly recalls or production stoppages, and maintain customer and market trust, all of which influence revenue and risk.
AI-generated analysis. Not financial advice.
04/13/2026 – 07:30 AM
Next-generation engineered probiotic targeting myostatin and Activin-A pathways advances toward clinical readiness across human and animal health applications
NEWPORT BEACH, Calif., April 13, 2026 (GLOBE NEWSWIRE) — NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a wholly owned subsidiary of PMGC Holdings Inc. (“PMGC” or the “Company”) (NASDAQ: ELAB), today announced a key development milestone for its asset, EL-32: the successful transfer of the EL-32 Working Cell Bank (“WCB”) to a U.S.-based third-party fermentation facility. This transfer initiates a manufacturing optimization program designed to increase production yield and establish a cost-efficient, scalable process in support of future clinical and commercial development.
EL-32 is a dual-action engineered probiotic therapeutic designed to express both myostatin and activin-A antigens, two key biological regulators of muscle development and metabolic function. By targeting both the myostatin and activin-A pathways through an oral, gut-mediated delivery mechanism, EL-32 offers a differentiated approach to preserving lean muscle mass and addressing metabolic dysfunction in patients undergoing GLP-1 receptor agonist weight loss therapy.
Modulant Biosciences LLC (“Modulant Biosciences”), licensee for the development, manufacture, and commercialization of products derived from EL-32 for non-human animal health applications under the previously announced License Agreement with NorthStrive Biosciences, has retained the third-party precision fermentation facility to lead upstream and downstream process development. This involves applying data-driven optimization strategies to improve yield, consistency, and manufacturability. NorthStrive Biosciences will work with Modulant Biosciences to leverage these efforts, with the goal of establishing a robust process foundation to support investigational new drug (“IND”)-enabling activities and future good manufacturing practices (“GMP”) manufacturing.
The parties’ collaboration reflects a dual-track development strategy: NorthStrive Biosciences retains all rights to human therapeutic applications of EL-32, while Modulant Biosciences holds an exclusive license to develop and commercialize EL-32-derived products for non-human animal health applications. This parallel approach is intended to maximize the commercial potential of the EL-32 platform across both markets while leveraging shared manufacturing and process development insights.
About NorthStrive Biosciences Inc.
NorthStrive Biosciences Inc., a PMGC Holdings Inc. (Nasdaq: ELAB) company, is a biopharmaceutical company focused on the development and acquisition of cutting-edge aesthetic medicines. Its assets include EL-22 and EL-32 which are engineered probiotic therapeutics targeting myostatin and activin-A pathways for muscle preservation in patients on GLP-1 receptor agonist weight loss therapies. For more information, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact: IR@pmgcholdings.com
FAQ
What did NorthStrive (ELAB) announce on April 13, 2026 about EL-32 manufacturing?
They transferred the EL-32 Working Cell Bank to a U.S. fermentation facility and began optimization. According to the company, this starts upstream and downstream process development to increase yield, consistency, and manufacturability for IND-enabling and future GMP efforts.
How does EL-32 target muscle preservation for patients on GLP-1 therapies (ELAB)?
EL-32 is an oral engineered probiotic expressing myostatin and activin-A antigens to preserve lean muscle. According to the company, the gut-mediated dual‑pathway approach aims to address muscle loss and metabolic dysfunction during GLP-1 receptor agonist weight-loss treatment.
What role does Modulant Biosciences play in EL-32 development announced by ELAB?
Modulant retained the third-party facility to lead fermentation process development for animal-health products. According to the company, Modulant holds an exclusive license for non-human applications while sharing process insights with NorthStrive for human programs.
Does the April 13, 2026 update from NorthStrive (ELAB) set an IND or clinical timeline for EL-32?
No specific IND or clinical timeline was provided in the announcement. According to the company, the current work focuses on establishing manufacturing and process foundations to support future IND-enabling activities and GMP manufacturing.
What manufacturing improvements is NorthStrive targeting for EL-32 (ELAB)?
The program targets increased production yield, consistency, and cost efficiency through data-driven optimization. According to the company, the third-party facility will apply upstream and downstream development to establish a scalable, manufacturable process for clinical and commercial use.
How does the dual-track development strategy affect EL-32 rights and commercialization (ELAB)?
NorthStrive retains human therapeutic rights while Modulant has exclusive animal-health rights for EL-32-derived products. According to the company, the parallel approach is intended to maximize commercial potential across human and non-human markets and share manufacturing learnings.
